The VES Deal

The one large acquisition

In 2021 Maximus paid about $1.36 billion for VES Group to enter federal clinical assessments, funding it almost entirely with new term debt [1]. Five years on the deal reads as value-accretive: U.S. Federal Services operating income has roughly tripled and its margin has nearly doubled [2]. The return is not secured — $380 million of the acquired intangibles, and the earnings behind them, ride on one VA contract that recompetes December 31, 2026 [3].

This is the one capital decision large enough to have reshaped the company, and no prior chapter has put a return on it. VES built the margin engine examined in Operating Leverage and, in the same stroke, concentrated the risk examined in Recompete Durability. Both sides of the report's central question trace to this transaction.

What was bought, and what was paid

Maximus acquired 100% of VES Group — a leading provider of medical disability examinations for the U.S. Department of Veterans Affairs — on May 28, 2021, for a cash price of $1,364.9 million, net of cash acquired, and folded it into U.S. Federal Services [4]. A second, smaller federal deal closed ten weeks earlier: the federal division of Attain, LLC, for $419.1 million on March 1, 2021 [5]. Together the two absorbed about $1.78 billion of capital in a single year and remade the segment.

Source: FY2021 Annual Report (Form 10-K), Note 6 — VES valuation and intangible asset table [6].

The allocation tells you what Maximus was actually buying. Of the $1.36 billion, $864 million landed in goodwill — the assembled workforce and the VA relationship — and $664 million in identifiable intangibles, of which $580 million was a single line: the customer contracts and relationships with the VA, assigned a 12-year life [7]. Net identifiable assets were only $501 million, and net of the deferred-tax and lease liabilities assumed, tangible assets were slightly negative [8]. Essentially the entire price was paid for a customer relationship and the earnings expected to flow from it.

Against production, that was a full price. In its first partial period — May 29 to September 30, 2021, roughly four months — VES contributed $186.6 million of revenue and $53.5 million of gross profit [9]. Annualized, that is about $545 million of revenue, so Maximus paid roughly 2.5 times sales for a services business — a multiple that only makes sense if the volume grows.

Sources: FY2021 Annual Report (Form 10-K), Note 6 [10] and Note 9 debt table [11]. Goodwill-plus-intangibles exceeds 100% of price because assumed net tangible liabilities offset it.

The funding was debt. To close VES, Maximus entered a new credit agreement; by September 30, 2021 total debt principal had gone from $29 million a year earlier to $1,523.5 million — Term Loan A of $1,086 million and Term Loan B of $399 million [12]. The 2021 coupon was low — near-zero LIBOR floors — but that same debt has since been refinanced at the ~5.4% blended rate laid out in Cash Conversion, so the deal's carrying cost rose well after the fact.

The immediate effect on reported earnings was negative. Loading a debt-funded, intangibles-heavy business onto the income statement roughly doubled amortization of intangibles to $90.5 million in fiscal 2022 (from $44.4 million) and roughly tripled interest expense to $46.0 million (from $14.7 million); operating margin fell from 9.6% to 7.0% and net income dropped from $291.2 million to $203.8 million [13]. Net income slid again to $161.8 million in fiscal 2023 and did not clear its pre-deal fiscal-2021 level until fiscal 2024 [14]. Fiscal 2021 carried unusually rich pandemic-response work, so part of that decline was normalization rather than the deal — but the amortization and interest were structural, and a shareholder judging the acquisition in 2023 had watched two straight years of falling earnings after a $1.36 billion outlay. The deal cost earnings before it added them.

The payoff arrived in the segment

VES is not reported as a standalone unit after integration, so a clean deal-level IRR is not computable from the filings; the honest read comes from the segment it was folded into. On that basis the case is straightforward. U.S. Federal Services operating income went from $132.9 million in FY2020 — the last full year before the deals — to $469.2 million in FY2025, and the segment margin climbed from 8.1% to 15.3% [15].

Source: derived from reported segment results, FY2020–FY2025 10-Ks; VES acquired May 2021, Attain March 2021 [16].

The revenue line that VES anchors makes the same point. Clinical Services revenue — VA medical examinations plus state-level assessments — grew from $539 million in FY2020 to $2,101 million in FY2025, close to a fourfold increase, and is now the largest of the four service lines Maximus reports [17]. VES did not merely add scale; it gave the company a federal-level clinical platform it had not previously had, and management points to synergy wins that "neither legacy company could successfully win" alone as the deal's intent "manifesting" [18].

Source: reported disaggregated revenue by service line, FY2020–FY2025 10-Ks [19].

Sizing the return

The segment gained $336 million of annual operating income between FY2020 and FY2025. Not all of that is the two deals — some is organic growth in legacy federal work, and part of the FY2024–FY2025 step-up is the cyclical volume bulge separated out in Operating Leverage. Crediting the acquisitions with the full increase implies a pre-tax return of about 19% on the $1.78 billion deployed; crediting them with only two-thirds of it drops that to roughly 13% pre-tax, or about 10% after Maximus's ~24% tax rate. Either figure clears a mid-single-digit-to-~9% cost of capital, so on the evidence available the 2021 federal M&A program has earned its keep.

One qualifier tempers how much of that return reflects deal-making skill. Much of the volume that lifted clinical revenue came from the PACT Act of August 2022, which expanded the conditions under which veterans qualify for benefits and, in Maximus's own words, "resulted in increases in MDE volumes" it expects to continue [20]. Maximus underwrote the platform; Congress supplied much of the demand fifteen months after the close. The acquisition bought the right asset in the right place, but the size of the payoff owes as much to an exogenous legislative tailwind as to the price paid or the integration.

One accounting wrinkle cuts in the deal's favor and is worth stating plainly. Reported operating income is charged with amortization of the acquired intangibles — $92.0 million across the company in FY2025, worth $1.17 of after-tax diluted EPS, the majority of it VES's $580 million customer-relationship asset [21]. That charge is non-cash: the cash the deal throws off exceeds the GAAP earnings it is credited with, which is why the returns above, struck on reported operating income, understate the cash economics somewhat.

What the return still rides on

The same allocation that made the deal a growth bet makes its durability a recompete bet. At March 31, 2026, $380.4 million of the original VES intangibles remained on the balance sheet — customer relationships and the medical provider network — and Maximus states outright that these assets "continue to support medical disability examinations (MDE) contracts with the U.S. Department of Veterans Affairs," are being amortized over a remaining life of about seven years, and that "in the event that our expectations change with respect to these acquired contracts, the value of these assets and the estimated remaining lives of these assets may need to be adjusted" [22].

That is an impairment warning attached to a single customer. The MDE contract that carries these assets runs through December 31, 2026 for all vendors; the VA has not released a rebid timeline, and management expects to learn one at an upcoming industry day, with a bridge extension possible but not confirmed [23]. The FY2025 10-K makes the exposure concrete at the company level: about one-fifth of revenue comes from a single federal agency, and the loss of a significant contract could bring "impairment charges related to tangible and intangible assets, including goodwill" [24].

Two facts sit on the other side of that risk. Maximus's own history is that recompete losses "typically affected approximately 7% to 10%" of the business a year, "largely being replaced by new or expanded work elsewhere" — a franchise that has absorbed rebids before [25]. And the goodwill itself is not yet in question: the July 1, 2025 annual test concluded it was not more likely than not that any reporting unit's fair value was below its carrying amount, with no impairment recorded [26].

The read

On the record to date, VES was a good use of $1.36 billion: a full entry price, paid almost entirely for a VA customer relationship, that execution has vindicated by turning U.S. Federal Services into the company's earnings engine. The strongest fact against treating that as settled is that $380 million of the acquired intangibles and the record segment margin behind them both rest on the one contract up for rebid on December 31, 2026 — the deal built the margin engine and concentrated the risk in the same asset. What would change the read is the rebid outcome: a clean VES retention converts the acquisition from accretive-so-far to durably accretive; a loss would trigger the intangible impairment management has already flagged and pull the segment margin back toward its pre-deal level. The deal's verdict and the report's central question resolve on the same day.